Response to NHS Commercial Framework consultation
NHS England has published a consultation document which sets out proposals for updating the NHS Commercial Framework for New Medicines. The proposals include:
- indication-specific pricing arrangements and the circumstances in which they will be considered
- a reflection of the Competition and Markets Authority prioritisation statement on combination therapies
- embedding the provisions and principles supporting patient access schemes into the Commercial framework for new medicines
The BIA has responded to the consultation on updating the NHS commercial framework for new medicines. We welcome the emphasis on indication-specific pricing (ISP) in supporting access to new indications for a given medicine and recommend a number of changes to the proposed criteria for ISP in order to ensure that patients can benefit from these treatments.
